{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:08:48Z","timestamp":1790665728741,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jcv.2014.03.002","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T06:17:54Z","timestamp":1395037074000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy"],"prefix":"10.1016","volume":"60","author":[{"given":"Soren","family":"Gantt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Cattamanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Krantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Selke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meei-Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Casper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2014.03.002_bib0005","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/94.16.1204","article-title":"Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998","volume":"94","author":"Eltom","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jcv.2014.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMc070508","article-title":"HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load","volume":"357","author":"Maurer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2014.03.002_bib0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMc072994","article-title":"More on HIV-associated Kaposi's sarcoma","volume":"358","author":"Krown","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2014.03.002_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-med-050409-103711","article-title":"The increasing burden of HIV-associated malignancies in resource-limited regions","volume":"62","author":"Casper","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jcv.2014.03.002_bib0025","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/00002030-200005260-00010","article-title":"Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients CISIH 92. Centre d\u2019information et de soins de l\u2019immunodeficience humaine","volume":"14","author":"Dupont","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2133.1999.02818.x","article-title":"The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma","volume":"140","author":"Dupin","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0035","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","article-title":"Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma","volume":"12","author":"Lebbe","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0040","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/QAD.0b013e328182df03","article-title":"Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART\/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma","volume":"21","author":"Bihl","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0045","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/QAD.0b013e3282ff6275","article-title":"Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response","volume":"22","author":"Nguyen","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0050","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(95)91619-9","article-title":"Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma","volume":"346","author":"Whitby","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2014.03.002_bib0055","first-page":"283","article-title":"HHV-8 DNA in blood and the development of HIV-associated Kaposi's sarcoma in the era of HAART--a prospective evaluation","volume":"7","author":"Lorenzen","year":"2002","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jcv.2014.03.002_bib0060","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/00002030-200009290-00006","article-title":"Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage","volume":"14","author":"Campbell","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002030-200301240-00012","article-title":"Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus","volume":"17","author":"Cannon","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0070","first-page":"1222","article-title":"Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance","volume":"9","author":"Broccolo","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0075","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00126334-200212010-00003","article-title":"Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma","volume":"31","author":"Gill","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2014.03.002_bib0080","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/00002030-200308150-00015","article-title":"Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma","volume":"17","author":"Engels","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0085","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1046\/j.0022-202x.2001.01465.x","article-title":"Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy","volume":"117","author":"Pellet","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0090","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/1096-9071(200012)62:4<416::AID-JMV4>3.0.CO;2-Z","article-title":"Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients","volume":"62","author":"Leao","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0095","doi-asserted-by":"crossref","DOI":"10.1086\/654800","article-title":"Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe","author":"Borok","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2014.03.002_bib0100","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1128\/JVI.76.6.2634-2640.2002","volume":"76","author":"Wilkinson","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0105","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/1521-4141(2002010)32:10<2711::AID-IMMU2711>3.0.CO;2-3","article-title":"NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma","volume":"32","author":"Sirianni","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.15.2.310-326.2002","article-title":"Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma","volume":"15","author":"Barillari","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jcv.2014.03.002_bib0115","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/viro.2002.1434","article-title":"Human immunodeficiency virus type-1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus through induction of KSHV Rta","volume":"297","author":"Varthakavi","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.jcv.2014.03.002_bib0120","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1097\/00002030-200307040-00028","article-title":"Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen","volume":"17","author":"Bani-Sadr","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1310\/VQXJ-41X6-GJA2-H6AG","article-title":"Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy","volume":"4","author":"Leitch","year":"2003","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jcv.2014.03.002_bib0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00126334-200108150-00006","article-title":"Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks","volume":"27","author":"Rey","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2014.03.002_bib0135","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/00002030-200307250-00001","article-title":"A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma","volume":"17","author":"Portsmouth","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0140","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/sj.bjc.6603056","article-title":"Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy","volume":"94","author":"Martinez","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcv.2014.03.002_bib0145","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/QAI.0b013e3181aa13c7","article-title":"The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients","volume":"51","author":"Crum-Cianflone","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2014.03.002_bib0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/QCO.0b013e3283486d04","article-title":"Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment","volume":"24","author":"Gantt","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jcv.2014.03.002_bib0155","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/COH.0b013e328313915d","article-title":"Repositioning HIV protease inhibitors as cancer therapeutics","volume":"3","author":"Bernstein","year":"2008","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","article-title":"Anti-HIV drugs for cancer therapeutics: back to the future?","volume":"10","author":"Chow","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0165","first-page":"25","article-title":"Insights into the broad cellular effects of nelfinavir and the hiv protease inhibitors supporting their role in cancer treatment and prevention","author":"Gantt","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0170","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/AAC.01295-10","article-title":"The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro","volume":"55","author":"Gantt","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcv.2014.03.002_bib0175","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/JVI.74.2.684-692.2000","article-title":"Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir","volume":"74","author":"Gustafson","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0180","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jac\/49.2.359","article-title":"Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase","volume":"49","author":"Lock","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcv.2014.03.002_bib0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/rmv.341","article-title":"HHV-8 infection: a model for reactivation and transmission","volume":"12","author":"Corey","year":"2002","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00126334-200403010-00003","article-title":"HIV infection and human herpesvirus-8 oral shedding among men who have sex with men","volume":"35","author":"Casper","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2014.03.002_bib0195","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/JCM.37.6.1941-1947.1999","article-title":"Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples","volume":"37","author":"Ryncarz","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0200","doi-asserted-by":"crossref","first-page":"e 4222","DOI":"10.1371\/journal.pone.0004222","article-title":"Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcv.2014.03.002_bib0205","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/JCM.40.10.3822-3825.2002","article-title":"Assessment of a combined testing strategy for detection of antibodies to human herpesvirus 8 (HHV-8) in persons with Kaposi's sarcoma, persons with asymptomatic HHV-8 infection, and persons at low risk for HHV-8 infection","volume":"40","author":"Casper","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0210","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM200011093431904","article-title":"Mucosal shedding of human herpesvirus 8 in men","volume":"343","author":"Pauk","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2014.03.002_bib0215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/509621","article-title":"Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men","volume":"195","author":"Casper","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2014.03.002_bib0220","series-title":"Analysis of longitudinal data","author":"Diggle","year":"2002"},{"key":"10.1016\/j.jcv.2014.03.002_bib0225","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hernan","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.jcv.2014.03.002_bib0230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/588820","article-title":"Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial","volume":"198","author":"Casper","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2014.03.002_bib0235","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1172\/JCI40567","article-title":"KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine","volume":"120","author":"Ganem","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcv.2014.03.002_bib0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nm0302-225","article-title":"HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma","volume":"8","author":"Sgadari","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jcv.2014.03.002_bib0245","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/blood.V99.10.3771","article-title":"Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma","volume":"99","author":"Pati","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcv.2014.03.002_bib0250","doi-asserted-by":"crossref","DOI":"10.1186\/1750-9378-7-S1-P33","article-title":"ER stress activates lytic gene expression in KSHV associated tumor cell lines. International Congress on Oncogenic Herpesviruses and Associated Diseases. Philadelphia, PA","author":"Kalu","year":"2012","journal-title":"Infect Agents Cancer"},{"key":"10.1016\/j.jcv.2014.03.002_bib0255","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1200\/JCO.2005.05.4072","article-title":"Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement","volume":"24","author":"Grabar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcv.2014.03.002_bib0260","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/00002030-199710001-00007","article-title":"Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir","volume":"11","author":"Conant","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0265","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ijc.11648","article-title":"The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma","volume":"108","author":"Stebbing","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcv.2014.03.002_bib0270","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/00002030-200405210-00024","article-title":"Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma?","volume":"18","author":"Ridolfo","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2014.03.002_bib0275","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/QAD.0b013e3283262a8d","article-title":"Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir","volume":"23","author":"Monini","year":"2009","journal-title":"AIDS"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653214000948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653214000948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T10:10:24Z","timestamp":1597572624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653214000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1386653214000948"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2014.03.002","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2014.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}